March 2026 Edition Welcome to The Legislative Dose, SlateRx’s regular briefing on the ever-evolving world of pharmacy benefits legislation. This brief report will provide insights and updates on policies,...
GLP-1 agents have reshaped the management of obesity, and the market continues to accelerate as new agents and indications emerge. On December 22, 2025, the FDA approved the first...
By Andy Gillespie, PharmD, AVP, Clinical Strategy, SlateRx As 2025 comes to a close, it’s time to look back at the year and how new therapies, evolving regulatory pressures,...
